Tags

Type your tag names separated by a space and hit enter

Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
J Nephrol. 2012 Jul-Aug; 25(4):460-72.JN

Abstract

Hyperlipidemia in the general population is strongly associated with an increased incidence of major adverse cardiovascular (CV) events (MACE). It is well established that HMG-CoA reductase inhibitors (statins) reduce CV and all-cause mortality in the general population, as well as in patients with CV disease (CVD). However, such a finding has not been definitively confirmed in patients with chronic kidney disease (CKD). Given that CV risk gradually increases with increasing stages of CKD (and is even higher in dialysis patients), it is of major relevance and importance to identify whether CKD patients might also benefit from alteration of lipid fractions, and how this might best be achieved. Bearing in mind that animal model and preclinical evidence suggests dyslipidemia might also be a factor promoting worsening renal function, it could legitimately be asked whether treating it may also therefore have a nephroprotective effect.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Heymann EP
Emergency Department, Cantonal Hospital, Neuchâtel, Switzerland.
Kassimatis TI
No affiliation info available
Goldsmith DJ
No affiliation info available

MeSH

AnimalsCardiovascular DiseasesChronic DiseaseDisease ProgressionDyslipidemiasEvidence-Based MedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKidneyKidney DiseasesRisk AssessmentRisk FactorsTreatment Outcome

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22641572

Citation

Heymann, Eric P., et al. "Dyslipidemia, Statins, and CKD Patients' Outcomes - Review of the Evidence in the Post-sharp Era." Journal of Nephrology, vol. 25, no. 4, 2012, pp. 460-72.
Heymann EP, Kassimatis TI, Goldsmith DJ. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era. J Nephrol. 2012;25(4):460-72.
Heymann, E. P., Kassimatis, T. I., & Goldsmith, D. J. (2012). Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era. Journal of Nephrology, 25(4), 460-72. https://doi.org/10.5301/jn.5000154
Heymann EP, Kassimatis TI, Goldsmith DJ. Dyslipidemia, Statins, and CKD Patients' Outcomes - Review of the Evidence in the Post-sharp Era. J Nephrol. 2012 Jul-Aug;25(4):460-72. PubMed PMID: 22641572.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era. AU - Heymann,Eric P, AU - Kassimatis,Theodoros I, AU - Goldsmith,David J A, PY - 2012/03/07/accepted PY - 2012/5/30/entrez PY - 2012/5/30/pubmed PY - 2012/11/14/medline SP - 460 EP - 72 JF - Journal of nephrology JO - J Nephrol VL - 25 IS - 4 N2 - Hyperlipidemia in the general population is strongly associated with an increased incidence of major adverse cardiovascular (CV) events (MACE). It is well established that HMG-CoA reductase inhibitors (statins) reduce CV and all-cause mortality in the general population, as well as in patients with CV disease (CVD). However, such a finding has not been definitively confirmed in patients with chronic kidney disease (CKD). Given that CV risk gradually increases with increasing stages of CKD (and is even higher in dialysis patients), it is of major relevance and importance to identify whether CKD patients might also benefit from alteration of lipid fractions, and how this might best be achieved. Bearing in mind that animal model and preclinical evidence suggests dyslipidemia might also be a factor promoting worsening renal function, it could legitimately be asked whether treating it may also therefore have a nephroprotective effect. SN - 1724-6059 UR - https://www.unboundmedicine.com/medline/citation/22641572/Dyslipidemia_statins_and_CKD_patients'_outcomes___review_of_the_evidence_in_the_post_sharp_era_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -